Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Atrial natriuretic factor receptor B, also known as natriuretic peptide receptor B (NPR-B) or NPR2, is a transmembrane receptor that primarily binds C-type natriuretic peptide (CNP). It is part of the guanylyl cyclase-coupled family of natriuretic peptide receptors. Upon binding its ligand, NPR-B catalyzes the conversion of GTP to cyclic GMP (cGMP), acting as a membrane-bound guanylyl cyclase. cGMP serves as a second messenger mediating downstream effects such as activation of cGMP-dependent protein kinases and modulation of ion channels. NPR-B plays a role in vasodilation, inhibition of vascular smooth muscle cell proliferation, regulation of atrial electrophysiology, and skeletal growth. Mutations in *NPR2* are associated with certain forms of skeletal dysplasia and may contribute to essential hypertension.
Binding of CNP leading to activation of guanylyl cyclase and increased cGMP production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Atrial Natriuretic Factor Receptor B (NPR-B).